Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor use

Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide

(2011) S. A. Polyzos et al.   OSTEOPOROSIS INTERNATIONAL

Regulation of circulating sclerostin levels by sex steroids in women and in men

(2010) Ulrike IL Mödder et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss

(2008) C A Wijbrandts et al.   ANNALS OF THE RHEUMATIC DISEASES

Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis

(2008) Kageyama Yasunori et al.   CLINICAL RHEUMATOLOGY

Osteocyte-Derived Sclerostin Inhibits Bone Formation: Its Role in Bone Morphogenetic Protein and Wnt Signaling

(2008) Peter ten Dijke et al.   JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME

Circulating Dickkopf-1 and Radiological Progression in Patients with Early Rheumatoid Arthritis Treated with Etanercept

(2008) Patrick Garnero et al.   JOURNAL OF RHEUMATOLOGY

Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor‐kappa B ligand, and high‐sensitivity C‐reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate

(2008) H. P. Sennels et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY